• CAR-T demonstrates efficacy as second-line therapy for transplant-ineligible lymphoma

    9 days ago - By Healio

    CHICAGO - Second-line therapy with lisocabtagene maraleucel induced initial complete remission among more than half of patients with relapsed or refractory transplant-ineligible large B-cell lymphoma, results from a phase 2 trial showed.
    A primary analysis from the PILOT study - presented at ASCO Annual Meeting - revealed low incidence of high-grade treatment-related cytokine release syndrome and neurotoxicity after a single dose of the cell therapy.
    Lisocabtagene maraleucel - a CD19-directed chimeric antigen receptor T-cell therapy
    Read more ...